Listing of all claims as amended

5 1.(PRESENTLY AMENDED) A peptide selected from the group having the formulae: $R_1-A^0-A^1-A^2-Asp-Ala-A^5-A^6-Thr-A^8-A^9-A^{10}-A^{11}-A^{12}-Val-Leu-A^{15}-A^{16}-Leu-Ser-A^{19}-A^{20}-A^{21}-A^{22}-Leu-Gln-Asp-Ile-A^{27}-A^{28}-A^{29}-A^{30}-R_2$

wherein R_1 is a member of the group consisting of a) PhAc, Hca, Dat, IndAc, Ipa, 1-Nac, 2-Nac, 1-Npr, 2-Npr, Ibu; $CH_3(CH_2)_nCO$, or $HOOC(CH_2)_nCO$, where n is an integer from 2 to 20,

10 and b) any other straight chain, branch chain, saturated, unsaturated or poly unsaturated aliphatic carboxyl group of 2-30 carbon atoms and any carbocyclic or heterocyclic aromatic carboxyl group of 3-8 carbon atoms containing at least one atom of the group S, N, and O in the heterocyclic ring,

A⁰ is Phe, D-Phe, Arg, D-Arg, or a carbon-nitrogen single bond is absent

A¹ is Tyr or His,

15 A² is D-Arg or D-Cit,

A⁵ is lle or Val,

A⁶ is Phe, Tyr, Nal, or Phe(Y), in which Y=F, Cl, Br, or I,

A⁸ is Asn, D-Asn, Cit, D-Cit, Gln, D-Gln, Ser, D-Ser, Thr, D-Thr, Ala, D-Ala, Abu, D-Abu, or Aib, A⁹ is His, D-His, Amp, D-Amp, Gup, or D-Gup,

20 A¹⁰ is Tyr, Tyr(Et), Tyr(Me); Phe(Y), in which Y=H, F, Cl, Br, or I; Amp, His, Cha, Chg, Bpa, Dip, Trp, Trp(For), Tpi, 1-Nal, 2-Nal, 3-Pal, 4-Pal, Phe(NH₂), or Phe(NO₂),

A¹¹ is His, D-His, Arg, D-Arg, Cit, Har, D-Har, Amp, D-Amp, Gup, or D-Gup,

A¹² is Lys, D-Lys, Orn, D-Orn, Har, D-Har, Cit, D-Cit, Nle, or Ala,

A¹⁵ is Gly, Ala, Abu, Aib, Nle, Gln, Cit, or His,

25 A¹⁶ is Gln or Arg,

A¹⁹ is Ala or Abu,

A²⁰ is His, D-His, Arg, D-Arg, or Cit,

A²¹ is Lys, D-Lys, Orn, D-Orn, Cit, or D-Cit,

A²² is Leu, Ala or Aib.

30 A²⁷ is Met, Leu, NIe, Abu, or D-Arg,

A²⁸ is Arg, D-Arg, Har, D-Har, Ser, Asn, Asp, Ala, Abu, or Cit,

A²⁹ is Arg. D-Arg. Har. D-Har. Cit. D-Cit. or Agm.

A³⁰ is Arg, D-Arg, Har, D-Har, Cit, D-Cit, Agm, or is a earbon nitrogen or earbon oxygen single bond absent,

35 R_2 is $-NH_2$, $-NH-NH_2$, -NH-OH, $-NHR_3$, $-NR_3R_4$, -OH, or $-OR_3$, in which R_3 and R_4 are any of C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkinyl, C_{7-16} phenylalkyl, $-C_6H_5$, or $-CH(C_6H_5)_2$; provided that if A^{29} is Agm then A^{30} and R_2 are absent, and if A^{30} is Agm then R_2 is absent, and pharmaceutically acceptable salts thereof.

2. (ORIGINAL) The compound of claim 1 wherein one or both of A¹¹ and A²⁰ are other than Arg, D-Arg, or Cit.

5 3. (ORIGINAL) A compound of claim 1 selected from the group consisting of:

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 67

10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 68

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, His⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 69

15

30

 $[CH_3(CH_2)_6CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Amp^9, Tyr(Me)^{10}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 70

 $[HOOC(CH_2)_8CO-Tyr^1,\ D-Arg^2,\ Phe(pCl)^6,\ Amp^9,\ Tyr(Me)^{10},\ Abu^{15},\ Nle^{27},\ D-Arg^{28},\ Har^{29}]hGH-20\ RH(1-29)NH_2$ Peptide 71

[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 72

25 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 73

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 74

[1-Nac-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 75

 $[CH_3(CH_2)_6CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, Amp^9, Tyr(Me)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, 35 Har^{29}]hGH-RH(1-29)NH_2$ Peptide 76

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Amp⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 77

```
. [CH_3(CH_2)_6CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, Amp^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2 Peptide 78
```

 $[CH_3(CH_2)_6CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, 5 Har^{29}]hGH-RH(1-29)NH_2$ Peptide 79

 $[CH_3(CH_2)_6CO -Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 80

10 [HOOC(CH₂)₈CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 81

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 82

15

30

 $[CH_3(CH_2)_6CO-Tyr^1, D-Arg^2, Phe(pCI)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, His^{20}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 86

 $[CH_3(CH_2)_6CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, Amp^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, His^{20}, Nle^{27}, D-Arg^{28},$ 20 Har²⁹]hGH-RH(1-29)NH₂ Peptide 87

[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 88

25 [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 89

[1-Nac-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 91

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 92

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Cit¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 35 Peptide 93

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, His¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 94

```
. [CH<sub>3</sub>(CH<sub>2</sub>)<sub>6</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, His<sup>9</sup>, Tyr(Et)<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, Orn<sup>21</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 95
```

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, 5 D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 96

 $[CH_3(CH_2)_6CO -Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NHEt$ Peptide 97

10 $[CH_3(CH_2)_8CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NHEt$ Peptide 98

[CH₃(CH₂)₁₀CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 99

15

30

[Hca -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 100

 $[CH_3(CH_2)_6CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, 20 Har^{29}]hGH-RH(1-29)NHMe$ Peptide 101

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 102

25 $[CH_3(CH_2)_6CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, Amp^9, Tyr(Et)^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Orn^{21}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 103

 $[CH_3(CH_2)_6CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Dip^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Orn^{21}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 104

 $[CH_3(CH_2)_6CO - Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Phe(pNO_2)^{10}, His^{11}, Orn^{12}, Abu^{15}, His^{20}, Orn^{21}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 105

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, 35 D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 106

[HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 107

```
[HOOC(CH<sub>2</sub>)<sub>12</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, His<sup>9</sup>, Dip<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, His<sup>20</sup>, Orn<sup>21</sup>, Nle<sup>27</sup>,
        D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub>
                                                                                                                   Peptide 108
        [HOOC(CH<sub>2</sub>)<sub>12</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, His<sup>9</sup>, Phe(pNO<sub>2</sub>)<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, His<sup>20</sup>,
   5 Orn<sup>21</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub>
                                                                                                                                    Peptide 109
        [HOOC(CH<sub>2</sub>)<sub>12</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, His<sup>9</sup>, Tyr(Et)<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, His<sup>20</sup>, Orn<sup>21</sup>,
        Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NHEt
                                                                                                                                    Peptide 110
10 [CH<sub>3</sub>(CH<sub>2</sub>)<sub>6</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, Amp<sup>9</sup>, Dip<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, His<sup>20</sup>, Orn<sup>21</sup>, Nle<sup>27</sup>,
        D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub>
                                                                                                                   Peptide 111
        [CH<sub>3</sub>(CH<sub>2</sub>)<sub>6</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, Amp<sup>9</sup>, Phe(pNO<sub>2</sub>)<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, His<sup>20</sup>, Orn<sup>21</sup>,
        Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub>
                                                                                                                   Peptide 112
15
       [CH<sub>3</sub>(CH<sub>2</sub>)<sub>6</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, Amp<sup>9</sup>, Tyr(Et)<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, His<sup>20</sup>, Orn<sup>21</sup>,
        Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NHEt
                                                                                                                                     Peptide 113
       [CH<sub>3</sub>(CH<sub>2</sub>)<sub>6</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, His<sup>9</sup>, Dip<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, His<sup>20</sup>, Orn<sup>21</sup>, Nle<sup>27</sup>, D-
20 Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NHEt
                                                                                                 Peptide 114
        [CH<sub>3</sub>(CH<sub>2</sub>)<sub>6</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, His<sup>9</sup>, Phe(pNO<sub>2</sub>)<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, His<sup>20</sup>, Orn<sup>21</sup>,
        Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NHEt
                                                                                                                                     Peptide 115
25 [HOOC(CH<sub>2</sub>)<sub>12</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, Amp<sup>9</sup>, Dip<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, His<sup>20</sup>, Orn<sup>21</sup>,
        Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub>
                                                                                                                   Peptide 116
        [HOOC(CH<sub>2</sub>)<sub>12</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, Amp<sup>9</sup>, Phe(pNO<sub>2</sub>)<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, His<sup>20</sup>,
       Orn<sup>21</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub>
                                                                                                                                  Peptide 117
30
        [CH<sub>3</sub>(CH<sub>2</sub>)<sub>6</sub>CO -Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Ala<sup>8</sup>, Amp<sup>9</sup>, Dip<sup>10</sup>, His<sup>11</sup>, Orn<sup>12</sup>, Abu<sup>15</sup>, His<sup>20</sup>, Orn<sup>21</sup>, Nle<sup>27</sup>,
        D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NHEt
                                                                                                                   Peptide 118
```

 $[HOOC(CH_2)_{12}CO \ -Tyr^1, \ D-Arg^2, \ Phe(pCl)^6, \ Ala^8, \ Amp^9, \ Dip^{10}, \ His^{11}, \ Orn^{12}, \ Abu^{15}, \ His^{20}, \ Orn^{21}, \ Nle^{27}, \ D-Arg^{28}, \ Har^{29}]hGH-RH(1-29)NHEt$ Peptide 120

[CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹,

Peptide 119

35 NIe²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt

. [HOOC(CH₂)₁₂CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, Amp⁹, Phe(pNO₂)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 121

- 5 4. (ORIGINAL) A compound of claim 3 selected from the group consisting of :
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 67
- 10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, His⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 69

[CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 70

15

[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Amp⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 72

- **20** $[CH_3(CH_2)_6CO Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, Amp^9, Tyr(Me)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 76
 - $[HOOC(CH_2)_{12}CO Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, Amp^9, Tyr(Me)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 77

25

 $[CH_3(CH_2)_6CO -Tyr^1, D-Arg^2, Phe(pCl)^6, Cit^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 79

- $[CH_{3}(CH_{2})_{6}CO \ -Tyr^{1}, \ D-Arg^{2}, \ Phe(pCl)^{6}, \ Ala^{8}, \ His^{9}, \ Tyr(Et)^{10}, \ His^{11}, \ Abu^{15}, \ Nle^{27}, \ D-Arg^{28}, \ 30 \ Har^{29}]hGH-RH(1-29)NH_{2}$ Peptide 80
 - [CH₃(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 86
- 35 $[CH_3(CH_2)_6CO Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Orn^{12}, Abu^{15}, Orn^{21}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 95
 - [CH₃(CH₂)₆CO -Tyr¹, D-Arg², Phe(pCl)⁶, Ala⁸, His⁹, Tyr(Et)¹⁰, His¹¹, Orn¹², Abu¹⁵, His²⁰, Orn²¹, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 96

. $[CH_3(CH_2)_6CO -Tyr^1, D-Arg^2, Phe(pCl)^6, Ala^8, His^9, Tyr(Et)^{10}, His^{11}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NHEt$ Peptide 97

5. (PRESENTLY AMENDED) A compound selected from the group consisting of:

5 $[CH_3(CH_2)_4CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Arg^9, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2 \\ Peptide 2$

- [HOOC(CH₂)₄CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 10 Peptide 3
 - $[CH_{3}(CH_{2})_{6}CO-Tyr^{1}, D-Arg^{2}, Phe(pCl)^{6}, Arg^{9}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_{2}$ Peptide 4
- 15 [HOOC(CH₂)₆CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 5
 - [CH₃(CH₂)₈CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 6

20 $[HOOC(CH_2)_8CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Arg^9, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 7

- $[CH_3(CH_2)_{10}CO-Tyr^1, D-Arg^2, Phe(pCl)^6, Arg^9, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 8
 - [HOOC(CH₂)₁₀CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 9
- **30** [CH₃(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 10
 - [HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 11

35 $[CH_{3}(CH_{2})_{14}CO-Tyr^{1}, D-Arg^{2}, Phe(pCl)^{6}, Arg^{9}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_{2} \\ Peptide 12$

[HOOC(CH₂)₁₄CO-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 40 Peptide 13 .

```
[CH_{3}(CH_{2})_{6}CO-Tyr^{1},\,D-Arg^{2},\,Phe(pCl)^{6},\,Arg^{9},\,Abu^{15},\,Nle^{27},\,Har^{28},\,D-Arg^{29}]hGH-RH(1-29)NH_{2} Peptide 14
```

- 5 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂ Peptide 15
 - [CH₃(CH₂)₁₄CO-Phe⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 16

10 $[CH_3(CH_2)_{14}CO-D-Phe^0, D-Arg^2, Phe(pCl)^6, Arg^9, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_2$ Peptide 17

[PhAc-Arg⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂

15 Peptide 18

[PhAc-D-Arg⁰, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 19

20 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 21

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 22

25 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Arg⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂ Peptide 23

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂ 30 Peptide 24

[HOOC(CH₂)₁₂CO-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁸, Cit⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 25

35 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, D-Ala⁸, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 26

[PhAc-Tyr¹, D-Arg², Pho(pCl)⁶, Abu⁸, Arg⁶, Abu¹⁵, Nlo²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂
——Poptide 27

- . [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Cit⁹, Abu¹⁵, Nle²⁷, Har²⁸, D-Arg²⁹]hGH-RH(1-29)NH₂ Peptide 28
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Amp¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 5 Peptide 30
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Amp¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 31
- 10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, His¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 32
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Cha¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 33
- 15 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tpi¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂

Peptide 34

- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, 2-Nal¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 20 Peptide 35
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Dip¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 36
- 25 $[PhAc-Tyr^{1}, D-Arg^{2}, Phe(pCl)^{6}, Har^{9}, Phe(pNH_{2})^{10}, Abu^{15}, Nle^{27}, D-Arg^{28}, Har^{29}]hGH-RH(1-29)NH_{2}$ Peptide 37
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Trp¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 38
- 30 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Phe(pNO₂)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 39
- [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, 3-Pal¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 35 Peptide 40
 - [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Et)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 41

```
. [PhAc-His<sup>1</sup>, D-Arg<sup>2</sup>, Tyr<sup>6</sup>, Har<sup>9</sup>, Bpa<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub>
Peptide 42
```

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Har¹², Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 5 Peptide 43

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 45

10 [PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 46

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 47

15

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 48

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Aib¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt 20 Peptide 49

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Orn¹², Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NHEt Peptide 50

25 [Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Agm²⁹]hGH-RH(1-29) Peptide 51

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Agm²⁹]hGH-RH(1-29) Peptide 52

30

[Hca-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Har³⁰]hGH-RH(1-30)NH₂ Peptide 53

[Dat-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Har³⁰]hGH-RH(1-30)NH₂ 35 Peptide 54

[lpa-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, Abu¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹, Har³⁰]hGH-RH(1-30)NH₂ Peptide 55

```
12
      [Hca-Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>, Har<sup>30</sup>]hGH-RH(1-
                                                     Peptide 56
       30)NHEt
      [Hca-Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, D-Arg<sup>29</sup>, Har<sup>30</sup>]hGH-RH(1-
   5 30)NH<sub>2</sub>
                                     Peptide 57
       [Hca-Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>, D-Arg<sup>30</sup>]hGH-RH(1-
       30)NH<sub>2</sub>
                                      Peptide 58
10 [Hca-Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>, Agm<sup>30</sup>]hGH-RH(1-30)
                      Peptide 59
       [PhAc-Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>, Agm<sup>30</sup>]hGH-RH(1-30)
                                      Peptide 60
15
      [PhAc-Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, His<sup>11</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-
       29)NH<sub>2</sub>
                                      Peptide 62
      [PhAc-Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Har<sup>11</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-
20 29)NH<sub>2</sub>
                                      Peptide 63
       [PhAc-Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Amp<sup>11</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-
       29)NH<sub>2</sub>
                                      Peptide 64
25 [PhAc-Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Cit<sup>11</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-
       29)NH<sub>2</sub>
                                      Peptide 65
       [PhAc-Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, His<sup>20</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-
```

29)NH₂ Peptide 84 30

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Har⁹, Tyr(Me)¹⁰, His¹¹, Abu¹⁵, His²⁰, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ Peptide 85

[PhAc-Tyr¹, D-Arg², Phe(pCl)⁶, Arg⁹, Cit¹⁵, Nle²⁷, D-Arg²⁸, Har²⁹]hGH-RH(1-29)NH₂ 35 Peptide 90

- 16. (PREVIOUSLY AMENDED)The method of suppressing IGF-I or IGF-II levels in the tumor tissue of a patient having a cancer carrying receptors for IGF-I by administering to said patient a suppressively effective amount of a compound of claim 1
- 5 17. (PREVIOUSLY AMENDED)The method of suppressing VEGF levels in the tumor tissue of a patient having a cancer by administering to said patient a suppressively effective amount of a compound of claim 1.
- 18. (PREVIOUSLY AMENDED)The method of suppressing levels of IGF-I in a patient in 10 need of same by administering to said patient a suppressively effective amount of a compound of claim 1.
- 19. (PREVIOUSLY AMENDED)The method of suppressing serum IGF-I levels in a patient having a cancer carrying receptors for IGF-I by administering to said patient a suppressively 15 effective amount of a compound of claim 1.
 - 20. (PREVIOUSLY AMENDED)The method of suppressing GH levels in a patient having a cancer carrying receptors for IGF-I or GH by administering to said patient a suppressively effective amount of a compound of claim 1.

20

- 21. Cancelled
- 22. (PRESENTLY AMENDED) A pharmacologically administrable composition for the suppression of levels of GH in a patient consisting essentially of a compound of claim 1 and a 25 pharmacologically acceptable carrier.
 - 23. 28 Cancelled